Skip to main content
Erschienen in: Inflammation 1/2015

01.02.2015

Potential Effects of Calcium Binding Protein S100A12 on Severity Evaluation and Curative Effect of Severe Acute Pancreatitis

verfasst von: Zhan Yinchu, Zhang Feng, Shi Yinsheng, Wu Fengqing, Zhou Xiaoyang, Li Jin, Gao Xiaofei

Erschienen in: Inflammation | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Severe acute pancreatitis is a life threatening disease with a high rate of mortality, but its treatments are still controversial. The purpose of this study is to investigate the potential effects of calcium binding protein S100A12 on severity evaluation and curative effect of severe acute pancreatitis induced by caerulein and lipopolysaccharide in mice. Intraperitoneal injection of 50 μg/kg caerulein for seven times (every interval time was an hour) and intraperitoneal injection of 10 mg/kg lipopolysaccharide for once to establish acute pancreatitis mice models. One hundred sixty specific pathogen-free imprinting control region (ICR) female mice were randomly divided into the control group (group A, normal saline), the mild group (group B, caerulein), the severe group (group C, caerulein + lipopolysaccharide), and the intervention group (group D, S100A12 recombinant antibodies + caerulein + lipopolysaccharide); each group had 40 mice. We sampled the blood at 8, 12, and 24 h after the beginning of building animal models. In each period of time, we respectively detected the serum S100A12, amylase (AMY), C-reactive protein (CRP), interleukin (IL-1β, IL-6), and tumor necrosis factor (TNF-α) levels. In addition, we observed and scored the pancreas and lungs histopathology of the mice. In each same period of time compared with group C, serum AMY, CRP, IL-1β, IL-6, TNF-α levels of group D were significantly decreased (p < 0.05). In each same period of time compared with group B and group C, serum S100A12 concentration of group D was significantly decreased (p < 0.05), and the pancreas and lungs histopathology were also much improved. These observations demonstrate that S100A12 recombinant antibodies were able to significantly reduce the severity of acute pancreatitis induced by caerulein and lipopolysaccharide in mice. Serum S100A12 may serve as a useful marker for disease severity and curative effect in mice with severe acute pancreatitis.
Literatur
1.
Zurück zum Zitat Sekimoto, M., T. Takada, Y. Kawarada, et al. 2006. JPN guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis. J Hepatobiliary Pancreat Surg 13: 10–24.CrossRefPubMedCentralPubMed Sekimoto, M., T. Takada, Y. Kawarada, et al. 2006. JPN guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis. J Hepatobiliary Pancreat Surg 13: 10–24.CrossRefPubMedCentralPubMed
2.
Zurück zum Zitat Granger, J., and D. Remick. 2005. Acute pancreatitis: models, markers, and mediators. Shock 24(Suppl 1): 45–51.CrossRefPubMed Granger, J., and D. Remick. 2005. Acute pancreatitis: models, markers, and mediators. Shock 24(Suppl 1): 45–51.CrossRefPubMed
3.
Zurück zum Zitat Mayerle, J., V. Hlouschek, and M.M. Lerch. 2005. Current management of acute pancreatitis. Nat Clin Pract Gastroenterol Hepatol 2: 473–483.CrossRefPubMed Mayerle, J., V. Hlouschek, and M.M. Lerch. 2005. Current management of acute pancreatitis. Nat Clin Pract Gastroenterol Hepatol 2: 473–483.CrossRefPubMed
4.
Zurück zum Zitat Scheiber-Camoretti, R., A. Mehrotra, L. Yan, J. Raman, J.F. Beshai, and M.A. Hofmann Bowman. 2013. Elevated S100A12 and sRAGE are associated with increased length of hospitalization after non-urgent coronary artery bypass grafting surgery. Am J Cardiovasc Dis 3(2): 85–90.PubMedCentralPubMed Scheiber-Camoretti, R., A. Mehrotra, L. Yan, J. Raman, J.F. Beshai, and M.A. Hofmann Bowman. 2013. Elevated S100A12 and sRAGE are associated with increased length of hospitalization after non-urgent coronary artery bypass grafting surgery. Am J Cardiovasc Dis 3(2): 85–90.PubMedCentralPubMed
5.
Zurück zum Zitat Shiotsu, Y., Y. Mori, M. Nishimura, T. Hatta, N. Imada, N. Maki, K. Iida, N. Iwamoto, E. Matsuoka, K. Tamagaki, and A. Kosaki. 2013. Prognostic utility of plasma S100A12 levels to establish a novel scoring system for predicting mortality in maintenance hemodialysis patients: a two-year prospective observational study in Japan. BMC Nephrol 16: 14–16. Shiotsu, Y., Y. Mori, M. Nishimura, T. Hatta, N. Imada, N. Maki, K. Iida, N. Iwamoto, E. Matsuoka, K. Tamagaki, and A. Kosaki. 2013. Prognostic utility of plasma S100A12 levels to establish a novel scoring system for predicting mortality in maintenance hemodialysis patients: a two-year prospective observational study in Japan. BMC Nephrol 16: 14–16.
6.
Zurück zum Zitat Saito, T., Y. Hojo, Y. Ogoyama, et al. 2012. S100A12 as a marker to predict cardiovascular events in patients with chronic coronary artery disease. Circ J 76(11): 2647–2652.CrossRefPubMed Saito, T., Y. Hojo, Y. Ogoyama, et al. 2012. S100A12 as a marker to predict cardiovascular events in patients with chronic coronary artery disease. Circ J 76(11): 2647–2652.CrossRefPubMed
7.
Zurück zum Zitat Shiotsu, Y., Y. Mori, M. Nishimura, et al. 2011. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol 6(4): 718–723.CrossRefPubMedCentralPubMed Shiotsu, Y., Y. Mori, M. Nishimura, et al. 2011. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol 6(4): 718–723.CrossRefPubMedCentralPubMed
8.
Zurück zum Zitat Mori, Y., A. Kosaki, N. Kishimoto, et al. 2009. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephroi 29(1): 18–24.CrossRef Mori, Y., A. Kosaki, N. Kishimoto, et al. 2009. Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephroi 29(1): 18–24.CrossRef
9.
Zurück zum Zitat Manolakis, A.C., A.N. Kapsoritakis, P. Georgoulias, et al. 2010. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol 10: 118.CrossRefPubMedCentralPubMed Manolakis, A.C., A.N. Kapsoritakis, P. Georgoulias, et al. 2010. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol 10: 118.CrossRefPubMedCentralPubMed
10.
Zurück zum Zitat Foell, D., T. Kucharzik, M. Kraft, et al. 2003. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52(6): 847–853.CrossRefPubMedCentralPubMed Foell, D., T. Kucharzik, M. Kraft, et al. 2003. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52(6): 847–853.CrossRefPubMedCentralPubMed
11.
Zurück zum Zitat Leach, S.T., Z. Yang, I. Messina, et al. 2007. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 42(11): 1321–1331.CrossRefPubMed Leach, S.T., Z. Yang, I. Messina, et al. 2007. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 42(11): 1321–1331.CrossRefPubMed
12.
Zurück zum Zitat Kaiser, T., J. Langhorst, H. Wittkowski, et al. 2007. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 56(12): 1706–1713.CrossRefPubMedCentralPubMed Kaiser, T., J. Langhorst, H. Wittkowski, et al. 2007. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 56(12): 1706–1713.CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Lorenz, E., M.S. Muhlebach, P.A. Tessier, et al. 2008. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med 102(4): 567–573.CrossRefPubMedCentralPubMed Lorenz, E., M.S. Muhlebach, P.A. Tessier, et al. 2008. Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med 102(4): 567–573.CrossRefPubMedCentralPubMed
14.
Zurück zum Zitat Foell, D., S. Seeliger, T. Vogl, H.G. Koch, H. Maschek, E. Harms, C. Sorg, and J. Roth. 2003. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 58(7): 613–617.CrossRefPubMedCentralPubMed Foell, D., S. Seeliger, T. Vogl, H.G. Koch, H. Maschek, E. Harms, C. Sorg, and J. Roth. 2003. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 58(7): 613–617.CrossRefPubMedCentralPubMed
15.
Zurück zum Zitat Wittkowski, H., A. Stumock, M.A. van Zoelen, et al. 2007. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 35(5): 1369–1375.CrossRefPubMed Wittkowski, H., A. Stumock, M.A. van Zoelen, et al. 2007. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 35(5): 1369–1375.CrossRefPubMed
16.
Zurück zum Zitat Shepherd, C.E., J. Goyette, V. Utter, et al. 2006. Inflammatory S100A9 and S100A12 proteins in Alzheimer’s disease. Neurobiol Aging 27(11): 1554–1563.CrossRefPubMed Shepherd, C.E., J. Goyette, V. Utter, et al. 2006. Inflammatory S100A9 and S100A12 proteins in Alzheimer’s disease. Neurobiol Aging 27(11): 1554–1563.CrossRefPubMed
17.
Zurück zum Zitat Komatsuda, A., H. Ohtani, H. Wakui, et al. 2006. Increased serum levels of S100A12 in patients with MPO-ANCA-associated glomerulonephritis. Clinical Nephrology 66(5): 315–321.CrossRefPubMed Komatsuda, A., H. Ohtani, H. Wakui, et al. 2006. Increased serum levels of S100A12 in patients with MPO-ANCA-associated glomerulonephritis. Clinical Nephrology 66(5): 315–321.CrossRefPubMed
18.
Zurück zum Zitat Kosaki, A., T. Hasegawa, T. Kimura, et al. 2004. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. Journal of Clinical Endocrinology Metabolism 89(11): 5423–5428.CrossRefPubMed Kosaki, A., T. Hasegawa, T. Kimura, et al. 2004. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. Journal of Clinical Endocrinology Metabolism 89(11): 5423–5428.CrossRefPubMed
19.
Zurück zum Zitat Liao, H., J. Wu, E. Kuhn, et al. 2004. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheumatism 50(12): 3792–3803.CrossRefPubMed Liao, H., J. Wu, E. Kuhn, et al. 2004. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheumatism 50(12): 3792–3803.CrossRefPubMed
20.
Zurück zum Zitat Foell, D., D. Kane, B. Bresnihan, et al. 2003. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 42(11): 1383–1389.CrossRef Foell, D., D. Kane, B. Bresnihan, et al. 2003. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 42(11): 1383–1389.CrossRef
21.
Zurück zum Zitat Foell, D., H. Wittkowski, I. Hammerschmidt, et al. 2004. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheumatism 50(4): 1286–1295.CrossRefPubMed Foell, D., H. Wittkowski, I. Hammerschmidt, et al. 2004. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheumatism 50(4): 1286–1295.CrossRefPubMed
22.
Zurück zum Zitat Ye, F., D. Foell, K. Hirono, et al. 2004. Neutrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease. American Journal of Cardiology 94(6): 840–844.CrossRefPubMed Ye, F., D. Foell, K. Hirono, et al. 2004. Neutrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease. American Journal of Cardiology 94(6): 840–844.CrossRefPubMed
23.
Zurück zum Zitat Foell, D., F. Ichida, T. Vogl, et al. 2003. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 361(9365): 1270–1272.CrossRefPubMed Foell, D., F. Ichida, T. Vogl, et al. 2003. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 361(9365): 1270–1272.CrossRefPubMed
24.
Zurück zum Zitat Guignard, F., J. Mauel, and M. Markert. 1995. Identification and characterization of a novel human neutrophil protein related to the S100 family. Biochem Journal 309(Pt 2): 395–401. Guignard, F., J. Mauel, and M. Markert. 1995. Identification and characterization of a novel human neutrophil protein related to the S100 family. Biochem Journal 309(Pt 2): 395–401.
25.
Zurück zum Zitat Pietzsch, J., and S. Hoppmann. 2009. Human S100A12: a novel key player in inflammation? Amino Acids 36(3): 381–389.CrossRefPubMed Pietzsch, J., and S. Hoppmann. 2009. Human S100A12: a novel key player in inflammation? Amino Acids 36(3): 381–389.CrossRefPubMed
26.
Zurück zum Zitat Schmidt, J., D.W. Rattner, K. Lewandrowski, C.C. Compton, U. Mandavilli, W.T. Knoefel, and A.L. Warshaw. 1992. A better model of acute pancreatitis for evaluating therapy. Annalytical Surgery 215(1): 44–56.CrossRef Schmidt, J., D.W. Rattner, K. Lewandrowski, C.C. Compton, U. Mandavilli, W.T. Knoefel, and A.L. Warshaw. 1992. A better model of acute pancreatitis for evaluating therapy. Annalytical Surgery 215(1): 44–56.CrossRef
27.
Zurück zum Zitat Schmidt, J., K. Lewandrowski, C. Fernandez-del Castillo, U. Mandavilli, C.C. Compton, A.L. Warshaw, and D.W. Rattner. 1992. Histopathologic correlates of serum amylase activity in acute experimental pancreatitis. Dig Dis Sci 37(9): 1426–1433.CrossRefPubMed Schmidt, J., K. Lewandrowski, C. Fernandez-del Castillo, U. Mandavilli, C.C. Compton, A.L. Warshaw, and D.W. Rattner. 1992. Histopathologic correlates of serum amylase activity in acute experimental pancreatitis. Dig Dis Sci 37(9): 1426–1433.CrossRefPubMed
28.
Zurück zum Zitat Sandler, R.S., J.E. Everhart, M. Donowitz, et al. 2002. The burden of selected digestive diseases in the United States. Gastroenterology 122: 1500–1511.CrossRefPubMed Sandler, R.S., J.E. Everhart, M. Donowitz, et al. 2002. The burden of selected digestive diseases in the United States. Gastroenterology 122: 1500–1511.CrossRefPubMed
29.
Zurück zum Zitat Christophe, R., C. Laurence, K. Scott, et al. 2002. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Research 62: 1868–1875. Christophe, R., C. Laurence, K. Scott, et al. 2002. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Research 62: 1868–1875.
30.
Zurück zum Zitat Rouleau, P., K. Vandal, C. Rvckman, et al. 2003. The calcium-binding protein S100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis. Clinical Immunology 107(1): 46–54.CrossRefPubMed Rouleau, P., K. Vandal, C. Rvckman, et al. 2003. The calcium-binding protein S100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis. Clinical Immunology 107(1): 46–54.CrossRefPubMed
31.
Zurück zum Zitat Mikkelsen, S.E., V. Novitskaya, M. Kriajevska, et al. 2001. S100A12 protein is a strong inducer of neurite outgrowth from primary hippocampal neurons. J Neuro 79(4): 767–776. Mikkelsen, S.E., V. Novitskaya, M. Kriajevska, et al. 2001. S100A12 protein is a strong inducer of neurite outgrowth from primary hippocampal neurons. J Neuro 79(4): 767–776.
32.
Zurück zum Zitat Gottsch, J.D., S.W. Eisinger, and S.H. Liu. 1999. Calgranulin C has filariacidal and filariastatic activity. Infect Immun 67(12): 6631–6636.PubMedCentralPubMed Gottsch, J.D., S.W. Eisinger, and S.H. Liu. 1999. Calgranulin C has filariacidal and filariastatic activity. Infect Immun 67(12): 6631–6636.PubMedCentralPubMed
33.
Zurück zum Zitat Steer, M. 2002. Pancreatitis severity: who calls the shots? Gastroenterology 122: 1168–1172.CrossRefPubMed Steer, M. 2002. Pancreatitis severity: who calls the shots? Gastroenterology 122: 1168–1172.CrossRefPubMed
34.
Zurück zum Zitat Sandoval, D., A. Gukovskaya, P. Reavey, et al. 1996. The role of neutrophils and platelet-activating factor in mediating experimental pancreatitis. Gastroenterology 111: 1081–1091.CrossRefPubMed Sandoval, D., A. Gukovskaya, P. Reavey, et al. 1996. The role of neutrophils and platelet-activating factor in mediating experimental pancreatitis. Gastroenterology 111: 1081–1091.CrossRefPubMed
Metadaten
Titel
Potential Effects of Calcium Binding Protein S100A12 on Severity Evaluation and Curative Effect of Severe Acute Pancreatitis
verfasst von
Zhan Yinchu
Zhang Feng
Shi Yinsheng
Wu Fengqing
Zhou Xiaoyang
Li Jin
Gao Xiaofei
Publikationsdatum
01.02.2015
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 1/2015
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-0032-x

Weitere Artikel der Ausgabe 1/2015

Inflammation 1/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.